Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date: As of May 11, 2016, the issuer had 233,073,991 shares of common stock outstanding.
^^^^^ What a surprise, reporting ZERO cash for the 5th quarter in a row. Bob, are creditors threatenting to seize your bank accounts???? What kind of business shows ZERO cash 5 consecutive quarters? How does it operate with never any cash? Or are accounts drained completely at the end of every quarter?********
During the three months ended March 31, 2016, we received $16,909 from subscriber revenues.
During the three months ended March 31, 2016, we received $0 from license fees revenues.
Revenues
Revenues for the three months ended March 31, 2016 and 2015 were $16,488 and $44,701, respectively, a decrease of $28,213 or 63%. The decrease for the quarter was primarily due to a decline in licensing fees and the expiration of certain recurring revenue contracts. Despite the changing environment in the U.S. regarding patent laws, the Company continues to explore opportunities to monetize its domestic and international patent portfolio globally in both health information technology and biotechnology.
Operating expenses
Total operating expenses for the three months ended March 31, 2016 and 2015 were $428,534 and $619,443, respectively, a decrease of $190,889, or more than 31%. The decrease for the quarter was primarily due to a reduction in payroll, investor relations expenses, and marketing, legal and other consulting fees as part of the Company's efforts to continue streamlining expenses.
General and administrative expenses for the three months ended March 31, 2016 and 2015 were $376,199 and $461,992, respectively, a decrease of $85,793 or more than 18%. The decrease was primarily due to a reduction in legal expenses pertaining to patent prosecution, investor relations expenses, salaries, non-cash compensation expenses, and consulting expenses as part of the Company's efforts to continue streamlining operations.
Sales and marketing expenses for the three months ended March 31, 2016 and 2015 were $52,335 and $157,451, respectively, a decrease of $105,116, or 67%. The decrease was primarily due to lower business development fees and marketing consulting fees.
#1). You have money. Other people want it. All of it!
#2). You want easy money. So does everybody else. They'll get it, too....yours! (and all of it!)
#3). You tell yourself you're smart. You won't lose your money. Fact: Other people are smarter,
